Measuring patient-reported outcomes in advanced gastric cancer.
Measuring patient-reported outcomes in advanced gastric cancer.
复制标题
DOI：
10.3332/ecancer.2013.351
复制
发表时间：
2013
影响因子：
1.8
通讯作者：
Su Y
中科院分区：
文献类型：
--
作者：
Xu J;Evans TJ;Coon C;Copley-Merriman K;Su Y
胃癌（GC）是世界上最常见的癌症之一，通常在晚期才被诊断出来，且预后不良。治疗 GC 患者时，生活质量和患者报告结果 (PRO) 是重要的考虑因素。本研究的目的是确定适合用于 GC 试验的现有 PRO 仪器。数据来自系统文献综述和临床专家访谈。使用 OVID（EMBASE 和 MEDLINE）进行文献检索，获得 1,008 篇摘要； 92 个高级 GC 评估了 PRO。通过文献和专家意见确定的关键症状和功能影响包括腹痛或远处转移部位疼痛、吞咽困难和其他与饮食相关的症状以及消化系统症状。肝脏和肺部是最常见的转移部位，导致呼吸困难、腹部饱胀和黄疸。与排便习惯改变相关的症状在亚洲患者中似乎更为频繁和明显，这可能是由于该人群胃体中 GC 的患病率较高。确定了五种最常用的 PRO 仪器，但它们在晚期 GC 患者中的有效性仍不清楚。这里确定的症状和功能影响应通过晚期 GC 患者的可靠输入来确认。 GC 中 PRO 的最佳测量应考虑患者负担以及亚洲和非亚洲患者之间可能存在的差异。
Gastric cancer (GC), one of the most common cancers in the world, is often diagnosed at an advanced stage and associated with a poor prognosis. Quality of life and patient-reported outcomes (PROs) are important considerations when treating GC patients. The aim of this study was to identify existing PRO instruments that would be appropriate for use in GC trials. Data were obtained from a systematic literature review and interviews with clinical experts. A literature search was conducted using OVID (EMBASE and MEDLINE) and yielded 1,008 abstracts; 92 assessed PROs in an advanced GC. Key symptoms and functional impacts identified through the literature and expert input included abdominal pain or pain at the site of distant metastases, dysphagia and other symptoms related to eating, and digestive symptoms. The liver and lungs were the most frequent locations of metastases, leading to dyspnea, abdominal fullness, and jaundice. Symptoms related to changes in bowel habits appeared to be more frequent and pronounced in Asian patients, possibly due to the higher prevalence of GC in the body of the stomach in this population. The five most commonly used PRO instruments were identified, but their validity in advanced-stage GC patients remains unclear. The symptoms and functional impacts identified here should be confirmed with robust input from advanced-stage GC patients. Optimal measurement of PROs in GC should account for patient burden and possible differences between Asian and non-Asian patients.